Europe Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The Europe therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 14.76 billion by 2031, up from US$ 6.39 billion in 2024, with a compound annual growth rate (CAGR) of 12.7% during the period from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccines market in Europe is divided into several regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The growth of this market is driven by advanced healthcare systems and increased investments in research and development. Europe hosts numerous leading pharmaceutical and biotechnology companies that are dedicated to developing innovative vaccine therapies for various diseases, particularly cancer. The rising incidence of chronic diseases and the growing interest in personalized medicine are further propelling the demand for therapeutic vaccines in the region. The market is expected to continue its upward trajectory, bolstered by advancements in immunotherapy and the emergence of new vaccine technologies that present significant opportunities for growth.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented based on product type, technology, and end user:

By Product: The market includes cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
By End User: The end users are primarily hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

Therapeutic vaccines are designed to stimulate the immune system to treat conditions such as cancer, autoimmune diseases, and chronic infections. The increasing investments in vaccine development are crucial for the growth of the therapeutic vaccines market, fostering innovation and accelerating the creation of new treatments for chronic diseases. Over the last decade, global funding for vaccine R&D has surged, with governments, private entities, and pharmaceutical companies acknowledging the critical role of therapeutic vaccines in meeting unmet medical needs. For example, GlaxoSmithKline (GSK) allocated US$ 6.46 billion towards R&D in 2021, focusing on a pipeline that includes 43 medicines and 21 vaccines, with a significant portion targeting infectious diseases.

Moreover, there is a notable trend towards oncology-focused vaccines, with companies leveraging mRNA technology to develop therapeutic vaccines for various cancers. For instance, eTheRNA Immunotherapies received a €6.9 million grant from the European Commission to develop an innovative mRNA cancer vaccine for treating recurrent or metastatic HPV16+ cancers. Similarly, researchers at Queen's University Belfast secured funding to explore new treatments for triple-negative breast cancer, focusing on developing an mRNA vaccine that enhances the immune system's ability to target cancer cells with p53 mutations. Such funding initiatives are driving innovations in therapeutic vaccines, leading to more effective treatments for a range of diseases, including cancers and chronic infections.

Country Insights

The therapeutic vaccines market in Europe includes key countries such as Germany, Italy, France, the UK, Spain, and others, with Germany holding the largest market share in 2024. Germany boasts one of the most advanced healthcare systems globally, supported by a robust pharmaceutical and biotechnology sector that facilitates the development and commercialization of therapeutic vaccines. The country has a large patient population and a high demand for quality healthcare services. The increasing prevalence of chronic and infectious diseases, such as hepatitis B, further drives the market in Germany. For instance, in 2022, Germany reported 16,674 cases of hepatitis B.

Germany's strong research ecosystem, characterized by collaboration among academic institutions, hospitals, and biotech firms, is accelerating the development of new therapeutic vaccines. The German Cancer Research Center (DKFZ) is at the forefront of cancer immunotherapy research, contributing significantly to the country's innovation landscape. In August 2024, DKFZ researchers introduced a novel vaccine aimed at increasing HPV vaccination rates, demonstrating efficacy in protecting against various cancer-causing HPV types.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative products to consumers.

Product Code: BMIRE00032091

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Europe Therapeutic Vaccines Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Prevalence of Chronic Conditions
- 4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
- 4.2.1 Regulatory Challenges
4.3 Market Opportunities
- 4.3.1 Extending Product Pipeline
4.4 Future Trends
- 4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - Europe Market Analysis

5.1 Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 Europe Therapeutic Vaccines Market Forecast Analysis

6. Europe Therapeutic Vaccines Market Analysis - by Product

6.1 Cancer Vaccine
- 6.1.1 Overview
- 6.1.2 Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 infectious Disease Vaccine
- 6.2.1 Overview
- 6.2.2 infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
- 6.3.1 Overview
- 6.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. Europe Therapeutic Vaccines Market Analysis - by Technology

7.1 Allogenic Vaccine
- 7.1.1 Overview
- 7.1.2 Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
- 7.2.1 Overview
- 7.2.2 Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Europe Therapeutic Vaccines Market Analysis - by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
- 8.2.1 Overview
- 8.2.2 Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Europe Therapeutic Vaccines Market - Country Analysis

9.1 Europe
- 9.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
  - 9.1.1.2 Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.2.1 Germany: Europe Therapeutic Vaccines Market Share - by Product
    - 9.1.1.2.2 Germany: Europe Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.2.3 Germany: Europe Therapeutic Vaccines Market Share - by End User
  - 9.1.1.3 United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.3.1 United Kingdom: Europe Therapeutic Vaccines Market Share - by Product
    - 9.1.1.3.2 United Kingdom: Europe Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.3.3 United Kingdom: Europe Therapeutic Vaccines Market Share - by End User
  - 9.1.1.4 France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.4.1 France: Europe Therapeutic Vaccines Market Share - by Product
    - 9.1.1.4.2 France: Europe Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.4.3 France: Europe Therapeutic Vaccines Market Share - by End User
  - 9.1.1.5 Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.5.1 Italy: Europe Therapeutic Vaccines Market Share - by Product
    - 9.1.1.5.2 Italy: Europe Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.5.3 Italy: Europe Therapeutic Vaccines Market Share - by End User
  - 9.1.1.6 Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.6.1 Spain: Europe Therapeutic Vaccines Market Share - by Product
    - 9.1.1.6.2 Spain: Europe Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.6.3 Spain: Europe Therapeutic Vaccines Market Share - by End User
  - 9.1.1.7 Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
    - 9.1.1.7.1 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Product
    - 9.1.1.7.2 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Technology
    - 9.1.1.7.3 Rest of Europe: Europe Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Dendreon
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 BioNTech SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck & Co Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Amgen Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Transgene SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 THERAVECTYS SA
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 CureVac SE
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms